Patents by Inventor Andrew Siwkowski

Andrew Siwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION
    Publication number: 20080015162
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Application
    Filed: May 7, 2007
    Publication date: January 17, 2008
    Inventors: Sanjay Bhanot, Richard Geary, Robert McKay, Brett Monia, Punit Seth, Andrew Siwkowski, Eric Swayze, Edward Wancewicz
  • BACKBONE MODIFICATIONS TO MODULATE OLIGONUCLEOTIDE TARGETING IN VIVO
    Publication number: 20070299028
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes PTEN, SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Application
    Filed: February 26, 2007
    Publication date: December 27, 2007
    Inventors: Andrew Siwkowski, Edward Wancewicz, Thomas Leedom, Lynnetta Watts, Mausumee Guha, Brett Monia, Richard Griffey, Richard Geary, Scott Henry, Arthur Levin
  • Antisense Modulation of CD40 Expression
    Publication number: 20070161589
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.
    Type: Application
    Filed: August 22, 2006
    Publication date: July 12, 2007
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: C. Bennett, Lex Cowsert, Leila Malik, Andrew Siwkowski, Anne Eldrup
  • Enhanced antisense oligonucleotides
    Publication number: 20060063730
    Abstract: Described herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened antisense oligonucleotides.
    Type: Application
    Filed: September 19, 2005
    Publication date: March 23, 2006
    Inventors: Brett Monia, Andrew Siwkowski, Sanjay Bhanot
  • Modulation of SGLT2 expression
    Publication number: 20050191653
    Abstract: Compounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.
    Type: Application
    Filed: November 2, 2004
    Publication date: September 1, 2005
    Inventors: Susan Freier, Edward Wancewicz, Brett Monia, Andrew Siwkowski, Lynnetta Watts, Thomas Leedom
  • Antisense oligonucleotides optimized for kidney targeting
    Publication number: 20050113326
    Abstract: The present invention provides antisense compounds and methods for modulating the expression of target genes expressed in the kidney. In particular, this invention provides antisense oligonucleotide compounds optimized for targeting nucleic acid molecules expressed in the kidney. Such compounds are shown herein to efficiently modulate the expression of target genes SGLT2 and connective tissue growth factor (CTGF) in the kidney.
    Type: Application
    Filed: September 21, 2004
    Publication date: May 26, 2005
    Inventors: Andrew Siwkowski, Edward Wancewicz, Thomas Leedom, Lynnetta Watts, Mausumee Guha, Brett Monia
  • Antisense modulation of CD40 expression
    Publication number: 20040186071
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of CD40. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40. Methods of using these compounds for modulation of CD40 expression and for treatment of diseases associated with CD40 are provided.
    Type: Application
    Filed: October 31, 2003
    Publication date: September 23, 2004
    Inventors: C. Frank Bennett, Lex M. Cowsert, Leila Malik, Andrew Siwkowski, Anne B. Eldrup